Ofer N Gofrit1, Shalva Benjamin2, Sarel Halachmi3, Ilan Leibovitch4, Zohar Dotan5, Donald L Lamm6, Nahum Ehrlich7, Vladimir Yutkin8, Monique Ben-Am9, Abraham Hochberg10. 1. Hadassah Ein-Kerem Medical Center, Jerusalem, Israel. Electronic address: ogofrit@gmail.com. 2. Edith Wolfson Medical Center, Sackler Faculty of Medicine, Holon, Israel. 3. Bnai-Zion Medical Center, Haifa, Israel. 4. Meir Medical Center, Kfar Saba, Israel. 5. Sheba Medical Center, Tel Hashomer, Israel. 6. University of Arizona, Phoenix, Arizona. 7. Hillel Yafe Medical Center, Hadera, Israel. 8. Hadassah Ein-Kerem Medical Center, Jerusalem, Israel. 9. BioCancell Ltd., Jerusalem, Israel. 10. Hebrew University, Jerusalem, Israel.
Abstract
PURPOSE: H19 is a paternally imprinted oncofetal gene expressed in various embryonic tissues and in 85% of bladder tumors but suppressed in the adult healthy bladder. BC-819 is a DNA plasmid that carries the gene for diphtheria toxin-A under regulation of the H19 promoter sequence. We assessed the efficacy and toxicity of intravesical BC-819 instillations to prevent tumor recurrence and ablate a marker lesion in a phase 2b trial. MATERIALS AND METHODS: A total of 47 patients with recurrent, multiple nonmuscle invasive bladder tumors in whom priorintravesical therapy had failed underwent transurethral resection of all except 1 marker tumor. Patients expressing H19 received a 6-week induction course of intravesical BC-819. Patients who achieved a complete response (absent new tumors at 3 months) were given 3 maintenance courses of 3-weekly instillations every 3 months. RESULTS: All patients were evaluable for adverse effects and 39 were evaluable for efficacy. Complete tumor ablation was achieved in 33% of patients and in 64% there were no new tumors at 3 months. Median time to recurrence was 11.3 months in all cases but significantly longer (22.1 months) when analyzed by response status at 3 months. Adverse events were mild. The study was limited by the small number of patients. CONCLUSIONS:BC-819 prevented new tumor growth in two-thirds of the patients and ablated a third of the marker lesions. Prolonged time to recurrence was observed in responding patients. These results along with the good safety profile make BC-819 a potential medication for bladder cancer.
RCT Entities:
PURPOSE:H19 is a paternally imprinted oncofetal gene expressed in various embryonic tissues and in 85% of bladder tumors but suppressed in the adult healthy bladder. BC-819 is a DNA plasmid that carries the gene for diphtheria toxin-A under regulation of the H19 promoter sequence. We assessed the efficacy and toxicity of intravesical BC-819 instillations to prevent tumor recurrence and ablate a marker lesion in a phase 2b trial. MATERIALS AND METHODS: A total of 47 patients with recurrent, multiple nonmuscle invasive bladder tumors in whom prior intravesical therapy had failed underwent transurethral resection of all except 1 marker tumor. Patients expressing H19 received a 6-week induction course of intravesical BC-819. Patients who achieved a complete response (absent new tumors at 3 months) were given 3 maintenance courses of 3-weekly instillations every 3 months. RESULTS: All patients were evaluable for adverse effects and 39 were evaluable for efficacy. Complete tumor ablation was achieved in 33% of patients and in 64% there were no new tumors at 3 months. Median time to recurrence was 11.3 months in all cases but significantly longer (22.1 months) when analyzed by response status at 3 months. Adverse events were mild. The study was limited by the small number of patients. CONCLUSIONS:BC-819 prevented new tumor growth in two-thirds of the patients and ablated a third of the marker lesions. Prolonged time to recurrence was observed in responding patients. These results along with the good safety profile make BC-819 a potential medication for bladder cancer.
Authors: Mohammad A Obeid; Alaa A A Aljabali; Meriem Rezigue; Haneen Amawi; Hanin Alyamani; Shatha N Abdeljaber; Valerie A Ferro Journal: Methods Mol Biol Date: 2021
Authors: Mariya Shapovalova; John K Lee; Yingming Li; Donald J Vander Griend; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau Journal: Cancer Res Date: 2019-09-17 Impact factor: 12.701
Authors: Panagiotis Mastorakos; Clark Zhang; Eric Song; Young Eun Kim; Hee Won Park; Sneha Berry; Won Kyu Choi; Justin Hanes; Jung Soo Suk Journal: J Control Release Date: 2017-07-08 Impact factor: 9.776
Authors: Radha Munagala; Farrukh Aqil; Jeyaprakash Jeyabalan; Raghuram Kandimalla; Margaret Wallen; Neha Tyagi; Sarah Wilcher; Jun Yan; David J Schultz; Wendy Spencer; Ramesh C Gupta Journal: Cancer Lett Date: 2021-02-18 Impact factor: 8.679